 futur direct etoposid therapi etoposid import chemotherapeut agent treatment patient germ cell tumor lymphoma small cell lung cancer sclc optim use clear schedul depend critic import preliminari studi prolong schedul etoposid administr day effect standard schedul result sever phase II studi chronic oral etoposid administr induc occasion respons resist tumor higher-than-expect respons rate patient germ cell tumor sclc preliminari show etoposid absorpt low-dos schedul day observ etoposid new drug chronic schedul further explor schedul depend etoposid etoposid use patient gastric ovarian carcinoma unknown primari site sever drug synergist addit combin chemotherapi possibl topoisomeras inhibitor etoposid activ drug resist realm human test